NCT00190749View on ClinicalTrials.gov

Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder

PHASE4CompletedINTERVENTIONAL

Enrollment

130

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions

SchizophreniaSchizoaffective Disorder

Interventions

DRUG

olanzapine

5-20 mg, oral, capsules, daily, 12 weeks.

DRUG

risperidone

2-6 mg, oral, capsules, twice daily (BID), 12 weeks.

Trial Locations (1)

92161

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT00190749 - Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder | Biotech Hunter | Biotech Hunter